870281-83-7

Basic information

• Product Name: 2-Fluoro-6-nitro-N-phenylbenzamide
• Synonyms: 2-Fluoro-6-nitro-N-phenylbenzamide
• CAS NO: 870281-83-7
• Molecular Formula: C₁₃H₉FN₂O₃
• Molecular Weight: 260.2205632
• Mol File: 870281-83-7.mol

Chemical Properties

• Melting Point: 163-165℃
• Boiling Point: 342.4±32.0 °C(Predicted)
• Appearance: /
• Density: 1.411±0.06 g/cm3 (20℃ 760 Torr)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.57±0.70(Predicted)
• CAS DataBase Reference: 2-Fluoro-6-nitro-N-phenylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-6-nitro-N-phenylbenzamide(870281-83-7)
• EPA Substance Registry System: 2-Fluoro-6-nitro-N-phenylbenzamide(870281-83-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 870281-83-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluoro-6-nitro-N-phenylbenzamide is used as a pharmaceutical intermediate for the development of new drugs. Its unique structure, which includes a fluoro and nitro group, may contribute to the compound's biological activity and potential therapeutic effects.
Used in Organic Synthesis:
2-Fluoro-6-nitro-N-phenylbenzamide is used as an organic building block in the synthesis of various chemical compounds. Its presence of functional groups allows for further chemical reactions and modifications, enabling the creation of new molecules with specific properties and applications.
Safety Precautions:
Due to the complex structure and potential reactivity of 2-Fluoro-6-nitro-N-phenylbenzamide, it is essential to handle this compound with care. Strict safety measures should be implemented during its production, storage, and use to minimize the risk of accidents and ensure the safety of personnel and the environment.

Upstream product

• 7304-32-7 2-fluoro-5-nitrobenzoic acid 
• 62-53-3 aniline 
• 385-02-4 6-fluoro-2-nitrobenzoic acid 
• 50424-88-9 2-fluoro-6-nitrobenzoyl chloride 

Downstream Products

• 870281-84-8 (S)-[1-(2-fluoro-6-nitro-benzoy)phenylaminocarbonyl]propyl carbamic acid tert-butyl ester 
• 870281-86-0 (S)-2-(1-((9H-purin-6-yl-2,8-d2)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one 
• 1417456-04-2 2-amino-6-fluoro-N-phenyl-benzamide 
• 870281-82-6 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-3,4-dihydroquinazolin-4-one 
• 870281-85-9 (S)-(1-(5-fluoro-4-carbonyl-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamic acid tert-butyl ester 
• 1615255-70-3 (S)-2-(1-aminoethyl)-5-fluoro-3-phenylquinazolin-4(3H)-one 
• 1615254-09-5 (S)-tert-butyl (1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carbamate 

Relevant articles and documents

A novel strategy for the manufacture of idelalisib: Controlling the formation of an enantiomer

A novel and scalable synthesis of 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone, idelalisib 1, has been developed. This strategy controls the desfluoro impurity of 13 during reduction of nitro intermediate 4, and also arrests the formation of the enantiomer during cyclisation of diamide 17, without affecting the neighbouring chiral centre. This process is demonstrated on a larger scale in the laboratory and achieved good chemical and chiral purities coupled with good yields.

Substituted aminopyrimidine compounds and their method and use thereof

The invention relates to a new aminopyrimidine compound and an application thereof as a drug for treating disorder or diseases related to PI3-kinase abnormity in a free form or a pharmaceutically acceptable salt and preparation form. The invention also relates to a pharmaceutical composition which contains the new aminopyrimidine compound and an application of the pharmaceutical composition in treating mammal disorder or diseases and especially treating human disorder or diseases related to the PI3-kinase abnormity, such as treatment of immunity and inflammatory diseases of PI3-kinase regulation which plays a leading role in a leucocyte function and treatment of proliferative diseases which are related to PI3-kinase activity and include but not limited to leukaemia and solid tumor.

NOVEL PROCESS FOR PREPARATION OF IDELALISIB

The present invention provides the process for preparation of idelalisib or a pharmaceutically acceptable salt thereof using novel intermediates. The present invention 0 also provides polymorphic forms of the novel intermediates.

PROCESS FOR THE PREPARATION OF IDELALISIB

The present invention relates to a process for the preparation of idelalisib or a pharmaceutically acceptable salt thereof, via a novel intermediate namely, 2-fluoro-6-[[(2S)- 2-[[9-(methoxymethyl)purin-6-yl]amino]butanoyl]amino]-N-phenyl-benzamide.

Method for synthesizing [...]

The invention relates to the technical field of anti cancer drug idelalisib, and especially relates to an idelalisib synthetic method which is as follows: taking 2-fluoro-6 nitro benzoic acid as a raw material for reacting with phenylamine to produce a compound III under the catalytic effect of a condensing agent; using N-boc-L-2-amino butyric acid as a raw material for reacting with the compound III to produce a compound V under the catalytic effect of a condensing agent; reducing the compound V by a metal or a metal compound and an acidic solution for cyclization to obtain a compound VI; removing the BOC group by protection group removal to obtain a compound VII; taking the compound VII and 6-bromo purine for nucleophilic reaction to obtain idelalisib. According to the method, a intermediate link of acyl chloride production is not needed, the operation process is simplified, time and labor cost are saved, the after-treatment is simple, the reaction yield is improved, cost is reduced, and the method has the advantages of being mild in reaction condition, high in yield, green and environmentally friendly, and meets the requirements of industrial production.

Idelalisib intermediate and preparation method thereof

The invention discloses an Idelalisib new intermediate compound (V)(S)-2-{[3-fluoro-2-[(phenyl amino) carbonyl] phenyl] amino-1-ethyl}-amino acid butyl ester. According to the Idelalisib prepared by the intermediate, compared with the existing disclosed methods, the reaction is stable, the yield is high, the reaction condition is mild, the defects in the prior art are overcome, the Idelalisib intermediate is very suitable for industry large scale production, and the yield is higher than that of the existing method. (Please see the formula of the compound in the description.).

Preparation method of (S)-2-(1-amino-propyl)-5-fluoro-3-phenyl-3H-quinazoline-4-one

The invention discloses a preparation method of (S)-2-(1-amino-propyl)-5-fluoro-3-phenyl-3H-quinazoline-4-one. According to the method, a compound represented as a formula (V) is subjected to cyclization under the action of trimethylchlorosilane, (S)-[1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydro-quinazoline-2-yl) propyl]-isobutyl carbamate is obtained and subjected to BOC (t-butyloxycarboryl) de-protection through acid, and a product is obtained. A synthetic route provided by the invention overcomes defects in the prior art, has the advantages of being mild in reaction condition of each step, stable in reaction and high in yield, and is particularly applicable to industrial large-scale production of a key intermediate 6 of Idelalisib.

PROCESSES FOR PREPARATION OF IDELALISIB AND INTERMEDIATES THEREOF

The present application provides processes for preparation of Idelalisib and intermediates thereof. The present application also provides a process for purification of Idelalisib.

DEUTERATED QUINAZOLINONE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention related to deuterated quinazolinone compounds and pharmaceutical compositions comprising such compounds. In particular, disclosed are the deuterated quinazolinone compounds shown as formula (I), and the pharmaceutical compositions comprising such compounds or crystal form, pharmaceutically acceptable salts, hydrates or solvates thereof. The compounds of the present invention can be used for treating and/or preventing PI3K kinase-associated diseases, such as cancer, cell proliferative disease and the like.

A novel highly stereoselective synthesis of 2,3-disubstituted 3H-quinazoline-4-one derivatives

Figure presented An efficient three-step synthesis of chiral 3H-quinazoline-4-one derivatives from commercial materials is disclosed. The Mumm reaction of imidoyl chloride with α-amino acids followed by reductive cyclization affords enantiomerically pure (ee >93%) quinazoline-4-ones in good overall yield. A comparison with existing approaches indicates that this method is superior for hindered substrates.